Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Current Deferred Revenue (2020 - 2025)

Foghorn Therapeutics has reported Current Deferred Revenue over the past 6 years, most recently at $43.2 million for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $43.2 million for Q4 2025, down 5.29% from a year ago — trailing twelve months through Dec 2025 was $43.2 million (down 5.29% YoY), and the annual figure for FY2025 was $43.2 million, down 5.29%.
  • Current Deferred Revenue for Q4 2025 was $43.2 million at Foghorn Therapeutics, down from $65.3 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for FHTX hit a ceiling of $337.8 million in Q4 2021 and a floor of $1.3 million in Q3 2021.
  • Median Current Deferred Revenue over the past 5 years was $33.4 million (2023), compared with a mean of $63.6 million.
  • Biggest five-year swings in Current Deferred Revenue: soared 16589.72% in 2021 and later crashed 90.28% in 2022.
  • Foghorn Therapeutics' Current Deferred Revenue stood at $337.8 million in 2021, then crashed by 90.28% to $32.8 million in 2022, then grew by 5.27% to $34.6 million in 2023, then surged by 32.0% to $45.6 million in 2024, then dropped by 5.29% to $43.2 million in 2025.
  • The last three reported values for Current Deferred Revenue were $43.2 million (Q4 2025), $65.3 million (Q3 2025), and $59.7 million (Q2 2025) per Business Quant data.